GlobalData analysis suggests that China will lead with the highest number of prevalent cases of Alzheimer’s disease in 2033.

Climb Bio has entered an exclusive licence agreement with Beijing Mabworks Biotech for developing and commercialising CLYM116.

Following a string of FDA resignations, Patrizia Cavazzoni has announced that her last day will be 18 January.

A2 Biotherapeutics has secured $80m in funding to advance its pipeline of CAR-T cell therapies for solid tumour cancers.

Synaffix adds to the flurry of ADC dealmaking as it partners with Boehringer and Mitsubishi Tanabe with deals announced on the same day.

Light Horse’s CEO said the biotech’s initial focus will be on “high-value and historically challenging” oncology targets.

With clinical trials facing multiple challenges, digital solutions could provide the answer. We identify the key trends to ...

Aspect Biosystems has secured $115m in a Series B financing round to advance the development of bioprinted tissue therapeutics.

Financing was co-led by Forbion and General Atlantic, with participants including RA Capital Management, OrbiMed, and Lilly Asia Ventures.

The EC has approved the extension of Stallergenes Greer’s Palforzia for the treatment of peanut allergy in toddlers.

Orna will receive a $65m upfront payment and is eligible to receive potential milestone payments and royalties.

As part of the agreement, Sanofi will provide Alloy with upfront license fees and near-term preclinical milestone payments up to $27.5m.